RecruitingPhase 4NCT07594652
Medication Treatment of ADHD in Pediatric Epilepsy
Use of JornayPM® to Treat ADHD in Pediatric Epilepsy
Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Enrollment
25 participants
Start Date
May 29, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.
Eligibility
Min Age: 6 YearsMax Age: 17 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called methylphenidate hydrochloride (Jornay PM) for people with adhd - attention deficit disorder with hyperactivity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 17 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGmethylphenidate hydrochloride (Jornay PM)
all participants will receive active treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07594652
Related Trials
MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients
NCT07540585
Retail-Grade Weighted Blanket Effectiveness on ADHD-related Sleep Disturbances (BEAD)
NCT07588659
Psychophysiological Responses to Six Single-Session Self-Regulation Interventions in a Female Adult With ADHD and Stabilized Bipolar Disorder
NCT07437833
Acupuncture for ADHD: Acupoint Data Mining, Clinical Effectiveness, and Interviews to Explore Treatment Outcomes.
NCT068607631 location
Evaluation of the Relationship Between Medication, Eye Movements, and Autonomic Nervous System (ANS) Functions in Children and Adolescents With ADHD
NCT076348091 location